Int. J. Biosci.15(4), 95-100, October 2019
Immunizing human or animals with edible plants is an evolving tool that seems to grip countless potential. The selected/desired antigen of pathogens (HIV, tuberculosis etc) are inserted to the selected host plant by transformation technique to form a transgenic plant. Edible vaccines grip countless promise as a profitable, easily managing, can be store easily, unlikely or unable to fail and sociocultural gladly sustainable, particularly for the poor emerging nations. An edible vaccine takes the place of sore immunization methods. Compare to conventional vaccine, edible vaccine is inexpensive, needle free, eradicates the requirement for preservation, harmless, may be stored nearby to place of usage, and deliver mucosal and complete immunity. For the enhancing immunity in human and animal against Various type of infectious diseases such as cholera, measles, FMD and hepatitis B there are numerous types of edible vaccines are being developed. Edible vaccines also help to overpower auto immunity diseases alike type-I diabetes. Immunization generations and giving malnutrition have the dual advantages of edible vaccine. If the notable problem and challenges may be triumph over It also can bring about a destiny of more secure and further effective immunization.
Artnzen C. 1997. Edible vaccines. Public health reports 112, 190.
Chaitanya VK, Kumar JU. 2006. Edible vaccines. Sri Ramachandra Journal of Medicinal 1, 33-34.
Daniell H. 2007. Chloroplast transgenic approach to express and purify human serum albumin, a protein highly susceptible to proteolytic degradation. Google Patents.
Domansky N, Ehsani P, Salmanian AH, Medvedeva T. 1995. Organ-specific expression of hepatitis B surface antigen in potato. Biotechnology letters 17, 863-866.
Fischer R, Emans N. 2000. Molecular farming of pharmaceutical proteins. Transgenic research 9, 279-299.
Hassler S. 1995. Bananas and biotech consumers. Bio/Technology 13, 417.
Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki A. 1999. A plant-derived edible vaccine against hepatitis B virus. The FASEB journal 13, 1796-1799.
Kay RF, Madden RH, Van Schaik C, Higdon D. 1997. Primate species richness is determined by plant productivity: implications for conservation. Proceedings of the National Academy of Sciences 94, 13023-13027.
Knauf VC, Facciotti D. 1995. Genetic engineering of foods to reduce the risk of heart disease and cancer. Nutrition and Biotechnology in Heart Disease and Cancer. Springer.
Lee HL, Padmanabhan V, Whang S. 1997. Information distortion in a supply chain: the bullwhip effect. Management science 43, 546-558.
Matoh T, Kawaguchi S, Kobayashi M. 1996. Ubiquity of a borate-rhamnogalacturonan II complex in the cell walls of higher plants. Plant and cell physiology 37, 636-640.
Nakamura Y, Ito K, Isaksson LA. 1996. Emerging understanding of translation termination. Cell 87, 147-150.
Phoolcharoen W, Bhoo SH, Lai H, MA J, Arntzen CJ, Chen Q, Mason HS. 2011. Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana. Plant biotechnology journal 9, 807-816.
Prakash C. 1996. Edible vaccines and antibody producing plants. Biotechnology and Development Monitor 27, 10-13.
Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA, kent SJ, Strugnell RA, Suhrbicr A, Thomson SA. 1999. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunological reviews 171, 27-44.
Richter LJ, Thanavala Y, Arntzen CJ, Mason HS. 2000. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nature biotechnology 18, 1167.
Santos Majd, Wigdorovitz A, Trono K, Rı́OS, RD, Franzone PM, GIL F, Moreno J, Carrillo C, Escribano JM, Borca MV. 2002. A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants. Vaccine 20, 1141-1147.
Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. 1998. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature medicine 4, 607.
Tacket CO, Mason S, Losonsky G, Estes MK, Levine MM, Arntzen CJ. 2000. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. The journal of infectious diseases 182, 302-305.
Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. 2004. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 22, 4385-4389.
Tanghe A, Van Dijck P, Thevelein JM. 2006. Why do microorganisms have aquaporins? Trends in microbiology 14, 78-85.
Tripurani SK, Reddy N, Rao KS. 2003. Green revolution vaccines, edible vaccines. African Journal of Biotechnology 2, 679-683.
Waghulkar V. 2010. Fruit derived edible vaccines: Natural way for the vaccination. International Journal of Pharmaceutical Technical Research 2, 2124-2127.
Yusibov V, Hooper D, Spitsin S, Fleysh N, Kean R, Mikheeva T, Deka D, Karasev A, Cox S, Randall J. 2002. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 20, 3155-3164.